ORGANIZATIONAL ASPECTS OF IMMUNOPROPHYLAXIS OF INFECTIOUS DISEASES IN THE RUSSIAN FEDERATION

Abstract

The work studies the social significance of infectious diseases in the treatment and prevention of which immunobiological drugs play a major role. We have analyzed the current state of the Russian pharmaceutical market of immunobiological drugs included in the calendar of preventive vaccinations, the availability of which in the pharmaceutical market is a state guarantee for immunoprophylaxis of infectious diseases in the population. It was revealed that 18 items are represented in the national calendar of preventive vaccinations, and 92 trade names of immunobiological drugs are registered in the state register of medicines. By the number of registered trade names, polyvalent vaccines for flu prevention (16 names) and monovalent vaccines for measles prevention and tuberculosis prevention (12 names, respectively) are leading. 79.3% of the number of registered immunobiological drugs are made up of domestically produced drugs. Among domestic manufacturers, Microgen is the leader, with a 53.4% share in the range of immunobiological products supplied. СJSC «GlaxoSmithKline trading» is the leader among foreign manufacturers. The range of the abovementioned manufacturer is predominantly represented by combined antiviral vaccines for the prevention of measles, rubella and mumps (11 trade names).